The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Key NSCLC updates
Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines key non-small cell lung cancer (NSCLC) updates from the virtual Gathering Around Cancer 2020 Irish meeting, including novel targeted therapies designed for EGFR, ALK, ROS1, MET and KRAS mutated patients, as well as advances in immunotherapy such as combination ipilimumab and nivolumab which may show benefit in NSCLC patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)
